PMID- 37156482
OWN - NLM
STAT- MEDLINE
DCOM- 20230513
LR  - 20230622
IS  - 1540-1413 (Electronic)
IS  - 1540-1405 (Linking)
VI  - 21
IP  - 5
DP  - 2023 May
TI  - Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients 
      With Platinum-Resistant Ovarian Cancer: AURELIA Substudy.
PG  - 473-479.e4
LID - 10.6004/jnccn.2022.7101 [doi]
AB  - BACKGROUND: Current standards for toxicity reporting do not fully capture the 
      impact of adverse events (AEs) on patients' quality of life (QoL). This study 
      aimed to evaluate the association between toxicity and QoL by using toxicity 
      scores that take into account CTCAE grade grouping and AE duration and 
      cumulation. METHODS: Analyses were performed on the AURELIA trial dataset, 
      including 361 patients with platinum-resistant ovarian cancer treated with 
      chemotherapy alone or with bevacizumab. Global and physical functioning QoL were 
      issued from the EORTC QoL Questionnaire-Core 30 (QLQ-C30), collected at baseline 
      and 8/9 and 16/18 weeks after treatment initiation. Four toxicity scores were 
      computed: the total number of AEs, multiplied by their grade and not, and the 
      cumulative duration of AEs, weighted by their grade and not. Each score included 
      all AEs or only grade 3/4 nonlaboratory or treatment-related AEs. The 
      relationship between toxicity scores and QoL was assessed through linear mixed 
      regression. RESULTS: We found that 171 (47.5%) and 43 (11.9%) patients 
      experienced at least one grade 3 or 4 AE, respectively, whereas 113 (31.4%) 
      experienced grade 2 AEs only. Physical QoL was negatively associated with all 
      toxicity scores when computed with all grades of AEs (all P<.01), with a weaker 
      association when treatment-related AEs were considered. Global QoL was negatively 
      associated with toxicity scores computed with nonlaboratory all-grade AEs only 
      (beta, -3.42 to -3.13; all P<.01). Degrees of association were lower when 
      considering the AE duration. CONCLUSIONS: In this analysis of patients with 
      platinum-resistant ovarian cancer, toxicity scores based on the cumulative number 
      of AEs, modulated or not by grade, were more effective at predicting QoL changes 
      than those based on AE duration. Toxicity impact on QoL was better reflected when 
      grade 2 AEs were taken into account together with grade 3/4 AEs, whatever their 
      treatment imputability, and when laboratory AEs were excluded.
FAU - Lequesne, Justine
AU  - Lequesne J
AD  - Clinical Research, Francois Baclesse Center, Caen, France.
AD  - Anticipe (Interdisciplinary Research Unit for the Prevention and Treatment of 
      Cancer), INSERM Unit 1086, Caen, France.
FAU - Joly, Florence
AU  - Joly F
AD  - Clinical Research, Francois Baclesse Center, Caen, France.
AD  - Anticipe (Interdisciplinary Research Unit for the Prevention and Treatment of 
      Cancer), INSERM Unit 1086, Caen, France.
AD  - Medical Oncology Department, Francois Baclesse Center, Caen, France.
FAU - Peron, Julien
AU  - Peron J
AD  - Oncology Department, Lyon-Sud Hospital, Cancer Institute of Hospices Civils de 
      Lyon, Hospices Civils de Lyon, Lyon, France.
AD  - Laboratoire de Biometrie et Biologie Evolutive, Equipe Biostatistique-Sante, 
      Universite Claude Bernard Lyon 1, Villeurbanne, France.
FAU - Ray-Coquard, Isabelle
AU  - Ray-Coquard I
AD  - Department of Medical Oncology, Centre Leon Berard, Lyon, France.
FAU - Hardy-Bessard, Anne-Claire
AU  - Hardy-Bessard AC
AD  - Department of Medical Oncology, CARIO-HPCA, Plerin, France.
FAU - Selle, Frederic
AU  - Selle F
AD  - Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, 
      Paris, France.
FAU - Berton, Dominique
AU  - Berton D
AD  - Department of Medical Oncology, Institut de Cancerologie de l'Ouest-Rene 
      Gauducheau, Saint Herblain, France.
FAU - Follana, Philippe
AU  - Follana P
AD  - Department of Oncology, Centre Antoine Lacassagne, Nice, France.
FAU - Fabbro, Michel
AU  - Fabbro M
AD  - Medical Oncology Department, Institut Regional du Cancer de Montpellier, 
      Montpellier, France.
FAU - Lortholary, Alain
AU  - Lortholary A
AD  - Confluent Private Hospital, Institut de Cancerologie Catherine de Sienne, Nantes, 
      France.
FAU - Pujade-Lauraine, Eric
AU  - Pujade-Lauraine E
AD  - ARCAGY-GINECO Universite Paris Descartes, AP-HP, Paris, France.
FAU - Lefevre-Arbogast, Sophie
AU  - Lefevre-Arbogast S
AD  - Clinical Research, Francois Baclesse Center, Caen, France.
AD  - Anticipe (Interdisciplinary Research Unit for the Prevention and Treatment of 
      Cancer), INSERM Unit 1086, Caen, France.
FAU - Coquan, Elodie
AU  - Coquan E
AD  - Clinical Research, Francois Baclesse Center, Caen, France.
AD  - Medical Oncology Department, Francois Baclesse Center, Caen, France.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - J Natl Compr Canc Netw
JT  - Journal of the National Comprehensive Cancer Network : JNCCN
JID - 101162515
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Female
MH  - Humans
MH  - Bevacizumab/adverse effects
MH  - Carcinoma, Ovarian Epithelial
MH  - *Ovarian Neoplasms/drug therapy
MH  - *Quality of Life
OTO - NOTNLM
OT  - adverse events
OT  - ovarian cancer
OT  - quality of life
OT  - toxicity score
EDAT- 2023/05/09 00:42
MHDA- 2023/05/10 06:42
CRDT- 2023/05/08 19:24
PHST- 2022/07/22 00:00 [received]
PHST- 2022/11/21 00:00 [accepted]
PHST- 2023/05/10 06:42 [medline]
PHST- 2023/05/09 00:42 [pubmed]
PHST- 2023/05/08 19:24 [entrez]
AID - 10.6004/jnccn.2022.7101 [doi]
PST - ppublish
SO  - J Natl Compr Canc Netw. 2023 May;21(5):473-479.e4. doi: 10.6004/jnccn.2022.7101.